Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses of the prognostic factors of OS in AGC patients with SPM (n = 129)

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Variables Univariate analysis Multivariate analysis
HR [95% CI] p-value HR [95% CI] p-value
Regimen
 FP (vs. F) 0.56 [0.39–0.82] < 0.01 0.47 [0.31–0.72] < 0.01
Age
 ≥65 (vs. < 65) 0.80 [0.55–1.17] 0.25    
Sex
 Female (vs. male) 1.05 [0.72–1.54] 0.78    
PS
 2–4 (vs. 0–1) 1.22 [0.83–1.79] 0.32 0.95 [0.62–1.48] 0.83
Histology
 Intestinal (vs. diffuse) 0.71 [0.43–1.19] 0.19 0.70 [0.41–1.19] 0.18
 Unknown (vs. diffuse) NA   NA NA   NA
Disease status
 Recurrent (vs. advanced) 0.58 [0.25–1.32] 0.19 0.86 [0.36–2.10] 0.75
Primary site
 GEJ (vs. stomach) 0.98 [0.40–2.41] 0.96    
No. of metastatic sites
 ≥3 (vs. 1–2) 1.43 [0.92–2.23] 0.11 1.64 [0.97–2.76] 0.07
Target lesion
 Absence (vs. presence) 0.95 [0.65–1.38] 0.78    
Subtype of SPM
 Inadequate oral intake (vs. massive ascites) 0.81 [0.52–1.29] 0.38 0.58 [0.33–1.00] 0.05
 Both (vs. massive ascites) 1.09 [0.69–1.71] 0.71 0.76 [0.44–1.29] 0.31
Serum albumin level
 < 3.1 g/ml (vs. > 3.1 g/ml) 1.42 [0.97–2.07] 0.07 1.43 [0.94–2.17] 0.09
  1. AGC advanced gastric cancer, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, HR hazard ratio, NA not assessed, OS overall survival, SPM severe peritoneal metastasis